Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247013898> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2247013898 endingPage "22220" @default.
- W2247013898 startingPage "22220" @default.
- W2247013898 abstract "22220 Background: Factors potentially relevant in the yield of PBSC (CFU-GM and CD34+ cells) were evaluated in solid tumors (breast cancer 45, other than breast cancer 9), multiple myeloma (MM 75), clinically indolent or aggressive non-Hodgkin lymphoma (I-NHL 20, A- NHL 84) or classical Hodgkin lymphoma (HL, 38) patients. Methods: These factors were divided into host (age, disease histology and stage), therapeutic history before mobilization (mobilizing therapy during first or salvage treatment, number of cycles and of drugs used and exposure to alkylating agents or radiotherapy) and mobilizing program-related (type of mobilizing chemotherapy and type and dose of hemopoietic growth factor). Intermediate-dose chemotherapy consisted of 3–4g/m2 cyclophosphamide (CTX) or 800mg/m2 carboplatin (CBDCA) or 8mg/m2 mithoxantrone, 3g/m2 cytarabine and 8mg/m2 dexamethasone days 1–2 (miniMAD) or 100mg/m2 cisplatinum day 1, 4g/m2 cytarabine day 2, 40mg dexamethasone days 1–4 (DHAP) or 120mg/m2 epirubicin. The combination of 8 mg/m2 mithoxantrone, 4 g/m2 cytarabine and 8 mg/m2 dexamethasone days 1–3 (MAD) or 7 g/m2 CTX or ifosfamide 4g/m2 were defined as high- dose chemotherapy. Results: Linear regression analysis indicated that recovery of CFU-GM/Kg and CD34+cells/Kg was affected by disease type (decreasing from solid tumors to I-NHL) and amount of chemotherapy expressed as number of drugs or chemotherapy cycles given before mobilization. However, the CFU-GM/Kg cells yield, but not that of CD34+ cells/Kg was higher when G-CSF rather than GM-CSF was employed. The number of CD34+ cells/Kg recovered was significantly superior in pts in complete remission at the time of mobilization and in those not previously exposed to radiation therapy. The mobilizing scheme employed affected the CFU-GM/CD34+ cell ratio indicating that large numbers of more immature precursors were obtained when 7g/CTX or MAD were employed. Conclusions: The yield of PBSC was mainly related to patient history, previous exposure to chemotherapy, state of disease at mobilization and mobilization scheme. No significant financial relationships to disclose." @default.
- W2247013898 created "2016-06-24" @default.
- W2247013898 creator A5020465777 @default.
- W2247013898 creator A5026141761 @default.
- W2247013898 creator A5039870716 @default.
- W2247013898 creator A5043428545 @default.
- W2247013898 creator A5057001705 @default.
- W2247013898 creator A5057276481 @default.
- W2247013898 creator A5058985983 @default.
- W2247013898 creator A5066925260 @default.
- W2247013898 creator A5086138124 @default.
- W2247013898 creator A5090759974 @default.
- W2247013898 date "2008-05-20" @default.
- W2247013898 modified "2023-09-27" @default.
- W2247013898 title "The yield of peripheral blood stem cells (PBSC) in hematological or solid tumour patients treated with high dose chemotherapy and hemopoietic growth factors" @default.
- W2247013898 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.22220" @default.
- W2247013898 hasPublicationYear "2008" @default.
- W2247013898 type Work @default.
- W2247013898 sameAs 2247013898 @default.
- W2247013898 citedByCount "0" @default.
- W2247013898 crossrefType "journal-article" @default.
- W2247013898 hasAuthorship W2247013898A5020465777 @default.
- W2247013898 hasAuthorship W2247013898A5026141761 @default.
- W2247013898 hasAuthorship W2247013898A5039870716 @default.
- W2247013898 hasAuthorship W2247013898A5043428545 @default.
- W2247013898 hasAuthorship W2247013898A5057001705 @default.
- W2247013898 hasAuthorship W2247013898A5057276481 @default.
- W2247013898 hasAuthorship W2247013898A5058985983 @default.
- W2247013898 hasAuthorship W2247013898A5066925260 @default.
- W2247013898 hasAuthorship W2247013898A5086138124 @default.
- W2247013898 hasAuthorship W2247013898A5090759974 @default.
- W2247013898 hasConcept C126322002 @default.
- W2247013898 hasConcept C143998085 @default.
- W2247013898 hasConcept C2776694085 @default.
- W2247013898 hasConcept C2776755627 @default.
- W2247013898 hasConcept C2778041864 @default.
- W2247013898 hasConcept C2778239845 @default.
- W2247013898 hasConcept C2780835546 @default.
- W2247013898 hasConcept C2781451048 @default.
- W2247013898 hasConcept C71924100 @default.
- W2247013898 hasConcept C90924648 @default.
- W2247013898 hasConceptScore W2247013898C126322002 @default.
- W2247013898 hasConceptScore W2247013898C143998085 @default.
- W2247013898 hasConceptScore W2247013898C2776694085 @default.
- W2247013898 hasConceptScore W2247013898C2776755627 @default.
- W2247013898 hasConceptScore W2247013898C2778041864 @default.
- W2247013898 hasConceptScore W2247013898C2778239845 @default.
- W2247013898 hasConceptScore W2247013898C2780835546 @default.
- W2247013898 hasConceptScore W2247013898C2781451048 @default.
- W2247013898 hasConceptScore W2247013898C71924100 @default.
- W2247013898 hasConceptScore W2247013898C90924648 @default.
- W2247013898 hasIssue "15_suppl" @default.
- W2247013898 hasLocation W22470138981 @default.
- W2247013898 hasOpenAccess W2247013898 @default.
- W2247013898 hasPrimaryLocation W22470138981 @default.
- W2247013898 hasRelatedWork W2022103685 @default.
- W2247013898 hasRelatedWork W2062544888 @default.
- W2247013898 hasRelatedWork W2108334876 @default.
- W2247013898 hasRelatedWork W2277607698 @default.
- W2247013898 hasRelatedWork W2397786201 @default.
- W2247013898 hasRelatedWork W2416746630 @default.
- W2247013898 hasRelatedWork W2998042991 @default.
- W2247013898 hasRelatedWork W3024951534 @default.
- W2247013898 hasRelatedWork W3031289629 @default.
- W2247013898 hasRelatedWork W3089122812 @default.
- W2247013898 hasVolume "26" @default.
- W2247013898 isParatext "false" @default.
- W2247013898 isRetracted "false" @default.
- W2247013898 magId "2247013898" @default.
- W2247013898 workType "article" @default.